Nav: Home

Engineered cells could help tackle the third most common cancer in Chinese males

March 10, 2015

Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

The research, published in Cancer Immunology Research, explains how the team were able to create immune cells (T-cells) that use the presence of the Epstein-Barr virus to combat NPC.

NPC develops in the upper part of the throat known as the nasopharynx, which connects the back of your nose to the back of your mouth.

This particular cancer is unusually common throughout Southeast Asia, particularly in Southern China, where it is the third most common cancer in males. In this region, it accounts for 18% of all cancers*. Though early stage disease responds well to treatment, the more advanced cases have relatively low survival rates. As a result, there is a clear need for improved therapies for this cancer.

Work is ongoing into understanding why NPC is more prevalent in Southeast Asia than other regions. It is believed that it could stem from a mixture of environmental and genetic factors.

Epstein-Barr virus is consistently detected in malignant cells of NPC patients and, scientists believe, plays a role in the development of the tumours. The virus is ubiquitous in the human population where it usually persists as a life-long infection under the control of our immune cells.

Because it appears to be so closely linked with development of NPC, the research team were hopeful that the virus could be used as a gateway for an immune cell based therapy.

Dr Steve Lee, from the Cancer Immunology and Immunotherapy Centre at the University of Birmingham, explained, "There has been remarkable success in genetically engineering a patient's immune cells to treat tumours in recent trials for leukaemia. We wanted to take a similar approach to other cancers, namely NPC."

Current approaches for generating immune cells for NPC treatment are both time consuming and unreliable. The team think that this method of producing large numbers of specific immune cells within just a few days will provide more efficient treatments for patients.

Dr Lee added, "This research suggests that we might be able to make a real difference to NPC patients. The next step is to explore how we can test what we've found in the lab and develop a clinical trial."

There is further hope that the genetically engineered cells could prove useful in the treatment of other tumours that possess similar molecules. Target cells with the Epstein Barr virus protein LMP2, and the 'tissue type' molecule HLA A11 could also be treated. HLA11 is carried by more than half of the population of Southern China.
-end-


University of Birmingham

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.